PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature

Author:

Evangelista Laura12ORCID,Fiz Francesco34ORCID,Laudicella Riccardo5ORCID,Bianconi Francesco6ORCID,Castello Angelo7,Guglielmo Priscilla8,Liberini Virginia9ORCID,Manco Luigi10ORCID,Frantellizzi Viviana11ORCID,Giordano Alessia12,Urso Luca13ORCID,Panareo Stefano14ORCID,Palumbo Barbara15,Filippi Luca16ORCID

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Italy

2. IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy

3. Nuclear Medicine Department, E.O. “Ospedali Galliera”, 16128 Genoa, Italy

4. Nuclear Medicine Department and Clinical Molecular Imaging, University Hospital, 72076 Tübingen, Germany

5. Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, 90100 Palermo, Italy

6. Department of Engineering, Università degli Studi di Perugia, Via Goffredo Duranti, 06125 Perugia, Italy

7. Nuclear Medicine Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy

8. Nuclear Medicine Unit, Veneto Institute of Oncology IOV—IRCCS, 35128 Padua, Italy

9. Nuclear Medicine Department, S. Croce e Carle Hospital, 12100 Cuneo, Italy

10. Medical Physics Unit, Azienda USL of Ferrara, 45100 Ferrara, Italy

11. Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

12. Nuclear Medicine Unit, IRCCS CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy

13. Department of Nuclear Medicine PET/CT Centre, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy

14. Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, 41124 Modena, Italy

15. Section of Nuclear Medicine and Health Physics, Department of Medicine and Surgery, Università degli Studi di Perugia, 06125 Perugia, Italy

16. Nuclear Medicine Section, Santa Maria Goretti Hospital, 04100 Latina, Italy

Abstract

The aim of this review is to provide a comprehensive overview of the existing literature concerning the applications of positron emission tomography (PET) radiomics in lung cancer patient candidates or those undergoing immunotherapy. Materials and Methods: A systematic review was conducted on databases and web sources. English-language original articles were considered. The title and abstract were independently reviewed to evaluate study inclusion. Duplicate, out-of-topic, and review papers, or editorials, articles, and letters to editors were excluded. For each study, the radiomics analysis was assessed based on the radiomics quality score (RQS 2.0). The review was registered on the PROSPERO database with the number CRD42023402302. Results: Fifteen papers were included, thirteen were qualified as using conventional radiomics approaches, and two used deep learning radiomics. The content of each study was different; indeed, seven papers investigated the potential ability of radiomics to predict PD-L1 expression and tumor microenvironment before starting immunotherapy. Moreover, two evaluated the prediction of response, and four investigated the utility of radiomics to predict the response to immunotherapy. Finally, two papers investigated the prediction of adverse events due to immunotherapy. Conclusions: Radiomics is promising for the evaluation of TME and for the prediction of response to immunotherapy, but some limitations should be overcome.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference52 articles.

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., and Abbasi, N. (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 5, 1749–1768.

2. Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase in-hibition (TKI) that targets the VEGF receptor (VEGFR): Perspective on phase III clinical trials;Revels;J. Thorac. Dis.,2018

3. Current treatments for non-small cell lung cancer;Guo;Front. Oncol.,2022

4. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology;Mithoowani;Curr. Oncol.,2022

5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3